Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Preoperative BRAF Mutation is Predictive of Occult Contralateral Carcinoma in Patients with Unilateral Papillary Thyroid Microcarcinoma

  • Zhou, Yi-Li (Department of Oncology, The First Affiliated Hospital of Wenzhou Medical College) ;
  • Zhang, Wei (Department of Oncology, The First Affiliated Hospital of Wenzhou Medical College) ;
  • Gao, Er-Li (Department of Oncology, The First Affiliated Hospital of Wenzhou Medical College) ;
  • Dai, Xuan-Xuan (Department of Oncology, The First Affiliated Hospital of Wenzhou Medical College) ;
  • Yang, Han (Department of Oncology, The First Affiliated Hospital of Wenzhou Medical College) ;
  • Zhang, Xiao-Hua (Department of Oncology, The First Affiliated Hospital of Wenzhou Medical College) ;
  • Wang, Ou-Chen (Department of Oncology, The First Affiliated Hospital of Wenzhou Medical College)
  • Published : 2012.04.30
Download PDF
⟨ Previous Next ⟩

Abstract

Background and Objective: The optimal resection extent for clinically unilateral papillary thyroid microcarcinoma (PTMC) remains controversial. The objective was to investigate risk factors associated with occult contralateral carcinoma, and put emphasis on the predictive value of preoperative BRAF mutation. Materials and Methods: 100 clinically unilateral PTMC patients all newly diagnosed, previously untreated were analyzed in a prospective cohort study. We assessed the T1799A BRAF mutation status in FNAB specimens obtained from all PTMC patients before undergoing total thyroidectomy (TT) and central lymph node dissection (CLND) for PTMC. Univariate and multivariate analyses were used to reveal the incidence of contralateral occult cancer, difference of risk factors and predictive value, with respect to the following variables: preoperative BRAF mutation status, age, gender, tumor size, multifocality of primary tumor, capsular invasion, presence of Hashimoto thyroiditis and central lymph node metastasis. Results: 20 of 100 patients (20%) had occult contralateral lobe carcinoma. On multi-variate analysis, preoperative BRAF mutation (p = 0.030, OR = 3.439) and multifocality of the primary tumor (p = 0.004, OR = 9.570) were independent predictive factors for occult contralateral PTMC presence. However, there were no significant differences between the presence of occult contralateral carcinomas and age, gender, tumor size, capsular invasion, Hashimoto thyroiditis and central lymph node metastasis. Conclusions: Total thyroidectomy, including the contralateral lobe, should be considered for the treatment of unilateral PTMC if preoperative BRAF mutation is positive and/or if the observed lesion presents as a multifocal tumor in the unilateral lobe.

Keywords

References

  1. Baudin E, Travagli JP, Ropers J, et al (1998). Microcarcinoma of the thyroid gland: the Gustave-Roussy Institute experience. Cancer, 83, 553-9. https://doi.org/10.1002/(SICI)1097-0142(19980801)83:3<553::AID-CNCR25>3.0.CO;2-U
  2. Chow SM, Law SC, Chan JK, et al (2003). Papillary microcarcinoma of the thyroid-Prognostic significance of lymph node metastasis and multifocality. Cancer, 98, 31-40. https://doi.org/10.1002/cncr.11442
  3. Connor MP, Wells D, Schmalbach CE (2011). Variables predictive of bilateral occult papillary microcarcinoma following total thyroidectomy. Otolaryngol Head Neck Surg, 144, 210-5. https://doi.org/10.1177/0194599810391616
  4. Cooper DS, Doherty GM, Haugen BR, et al (2006). Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid, 16, 109-42. https://doi.org/10.1089/thy.2006.16.109
  5. Cooper DS, Doherty GM, Haugen BR, et al (2009). Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid, 19, 1167-214. https://doi.org/10.1089/thy.2009.0110
  6. Davies L, Welch HG (2006). Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA, 295, 2164-7. https://doi.org/10.1001/jama.295.18.2164
  7. Elisei R, Ugolini C, Viola D, et al (2008). BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J Clin Endocrinol Metab, 93, 3943-9. https://doi.org/10.1210/jc.2008-0607
  8. Grant CS, Hay ID, Gough IR, et al (1988). Local recurrence in papillary thyroid carcinoma: is extent of surgical resection important? Surgery, 104, 954-62.
  9. Gu LQ, Li FY, Zhao L, et al (2009). BRAFV600E mutation and X-linked inhibitor of apoptosis expression in papillary thyroid carcinoma. Thyroid, 19, 347-54. https://doi.org/10.1089/thy.2008.0246
  10. Hay ID, Grant CS, Taylor WF, et al (1987). Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system. Surgery, 102, 1088-95.
  11. Hay ID, Hutchinson ME, Gonzalez-Losada, et al (2008). Papillary thyroid microcarcinoma: a study of 900 cases observed in a 60-year period. Surgery, 144, 980-7; discussion 987-8. https://doi.org/10.1016/j.surg.2008.08.035
  12. Hwang E, Pakdaman MN, Black MJ, et al (2008). Tumour Size and Bilateral Thyroid Cancer after Thyroidectomy. J Otolaryngol Head Neck Surg, 139, 47. https://doi.org/10.1016/j.otohns.2008.01.018
  13. Hwang E, Pakdaman MN, Tamilia M, et al (2010). Bilateral papillary thyroid cancer and associated histopathologic findings. J Otolaryngol Head Neck Surg, 39, 284-7.
  14. Ito Y, Uruno T, Nakano K, et al (2003). An observation trial without surgical treatment in patients with papillary microcarcinoma of the thyroid. Thyroid, 13, 381-7. https://doi.org/10.1089/105072503321669875
  15. Jacquot-Laperriere S, Timoshenko AP, Dumollard JM, et al (2007). Papillary thyroid microcarcinoma: incidence and prognostic factors. Eur Arch Otorhinolaryngol, 264, 935-9. https://doi.org/10.1007/s00405-007-0290-4
  16. Kim ES, Kim TY, Koh JM, et al (2004). Completion thyroidectomy in patients with thyroid cancer who initially underwent unilateral operation. Clin Endocrinol (Oxf), 61, 145-8. https://doi.org/10.1111/j.1365-2265.2004.02065.x
  17. Kimura ET, Nikiforova MN, Zhu Z, et al (2003). High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res, 63, 1454-7.
  18. Koo BS, Lim HS, Lim YC, et al (2010). Occult contralateral carcinoma in patients with unilateral papillary thyroid microcarcinoma. Ann Surg Oncol, 17, 1101-5. https://doi.org/10.1245/s10434-009-0906-6
  19. Lin KL, Wang OC, Zhang XH, et al (2010). The BRAF mutation is predictive of aggressive clinicopathological characteristics in papillary thyroid microcarcinoma. Ann Surg Oncol, 17, 3294-300. https://doi.org/10.1245/s10434-010-1129-6
  20. Mercante G, Frasoldati A, Pedroni C, et al (2009). Prognostic factors affecting neck lymph node recurrence and distant metastasis in papillary microcarcinoma of the thyroid: results of a study in 445 patients. Thyroid, 19, 707-16. https://doi.org/10.1089/thy.2008.0270
  21. Nikiforova MN, Kimura ET, Gandhi M, et al (2003). BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab, 88, 5399-404. https://doi.org/10.1210/jc.2003-030838
  22. Noguchi S, Yamashita H, Murakami N, et al (1996). Small carcinomas of the thyroid. A long-term follow-up of 867 patients. Arch Surg, 131, 187-91. https://doi.org/10.1001/archsurg.1996.01430140077021
  23. Oler G, Cerutti JM (2009). High prevalence of BRAF mutation in a Brazilian cohort of patients with sporadic papillary thyroid carcinomas: correlation with more aggressive phenotype and decreased expression of iodide-metabolizing genes. Cancer, 115, 972-80. https://doi.org/10.1002/cncr.24118
  24. Pacini F, Elisei R, Capezzone M, et al (2001). Contralateral papillary thyroid cancer is frequent at completion thyroidectomy with no difference in low- and high-risk patients. Thyroid, 11, 877-81. https://doi.org/10.1089/105072501316973145
  25. Pasieka JL, Thompson NW, McLeod MK, et al (1992). The incidence of bilateral well-differentiated thyroid cancer found at completion thyroidectomy. World J Surg, 16, 711- 6; discussion 716-7. https://doi.org/10.1007/BF02067365
  26. Pelizzo MR, Boschin IM, Toniato A, et al (2006). Papillary thyroid microcarcinoma (PTMC): prognostic factors, management and outcome in 403 patients. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 32, 1144-8. https://doi.org/10.1016/j.ejso.2006.07.001
  27. Pitt SC, Sippel RS, and Chen H (2009). Contralateral papillary thyroid cancer: does size matter? Am J Surg, 197, 342-7. https://doi.org/10.1016/j.amjsurg.2008.09.011
  28. Schonberger J, Marienhagen J, Agha A, et al (2007). Papillary microcarcinoma and papillary cancer of the thyroid
  29. Sherman SI (2003). Thyroid carcinoma. Lancet, 361, 501-11. https://doi.org/10.1016/S0140-6736(03)12488-9
  30. Shindo M, Wu JC, Park EE, et al (2006). The importance of central compartment elective lymph node excision in the staging and treatment of papillary thyroid cancer. Arch Otolaryngol Head Neck Surg, 132, 650-4. https://doi.org/10.1001/archotol.132.6.650
  31. Wang W, Wang H, Teng X, et al (2010). Clonal analysis of bilateral, recurrent, and metastatic papillary thyroid carcinomas. Hum Pathol, 41, 1299-309. https://doi.org/10.1016/j.humpath.2010.02.008
  32. Wang W, Zhao W, Wang H, et al (2012). Poorer prognosis and higher prevalence of BRAF (V600E) mutation in synchronous bilateral papillary thyroid carcinoma. Ann Surg Oncol, 19, 31-6. https://doi.org/10.1245/s10434-011-2096-2
  33. Xing M (2007). BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev, 28, 742-62. https://doi.org/10.1210/er.2007-0007
  34. Zheng W, Zhang Z (2007). An analysis of cancer incidence in 2005 in Lucheng District, Wenzhou City, Zhejiang Province. Bulletin of Chinese Cancer, 16, 306-8.

Cited by

  1. Annual Financial Impact of Thyroidectomies for Nodular Thyroid Disease in China vol.15, pp.14, 2014, https://doi.org/10.7314/APJCP.2014.15.14.5921
  2. Coexistence of Histologically Confirmed Hashimoto’s Thyroiditis with Different Stages of Papillary Thyroid Carcinoma in a Consecutive Chinese Cohort vol.2014, pp.1687-8345, 2014, https://doi.org/10.1155/2014/769294
  3. Papillary Thyroid Microcarcinoma vol.22, pp.2, 2014, https://doi.org/10.1177/1066896913517394
  4. The BRAF V600E mutation in papillary thyroid cancer with positive or suspected pre-surgical cytological finding is not associated with advanced stages or worse prognosis vol.45, pp.3, 2014, https://doi.org/10.1007/s12020-013-0029-5
  5. Imaging, genetic testing, and biomarker assessment of follicular cell-derived thyroid cancer vol.46, pp.6, 2014, https://doi.org/10.3109/07853890.2014.923739
  6. Mutation is not Associated with Occult Contralateral Carcinoma in Patients with Unilateral Papillary Thyroid Microcarcinoma vol.16, pp.7, 2015, https://doi.org/10.7314/APJCP.2015.16.7.2947
  7. Characteristics of contralateral carcinomas in patients with differentiated thyroid cancer larger than 1 cm vol.401, pp.3, 2016, https://doi.org/10.1007/s00423-016-1393-4
  8. Role of stem cell growth factor/c-Kit in the pathogenesis of irritable bowel syndrome vol.13, pp.4, 2017, https://doi.org/10.3892/etm.2017.4133
  9. Predicting Factors for Bilaterality in Papillary Thyroid Carcinoma with Tumor Size <4 cm vol.27, pp.2, 2017, https://doi.org/10.1089/thy.2016.0190
  10. Clinical and Pathologic Predictors of Lymph Node Metastasis and Recurrence in Papillary Thyroid Microcarcinoma vol.26, pp.6, 2016, https://doi.org/10.1089/thy.2015.0429